Subcutaneous (SubQ) injections deliver a medication into the fatty tissue just under the skin
as of 2026 lands in these ranges: Semaglutide (Wegovy): $1,100 to $1,400 per month at retail Tirzepatide (Zepbound): $1,000 to $1,300 per month at retail Sermorelin (compounded): $200 to $400 per month at a licensed clinic CJC-1295 + Ipamorelin (compounded): $250 to $450 per month Insurance coverage for Wegovy and Zepbound has improved in 2026 but remains inconsistent
In losing Novo as a partner, Hims forfeited far more than a single co-marketing agreement
Common medications used in medically supervised programs include semaglutide and tirzepatide, which are often incorporated into a structured GLP-1 weight loss program
[DOI] [PMC free article] [PubMed] [Google Scholar] 37.Zhang F., Zhong R.J., Cheng C., Li S., Le W.D